PMC:7189872 / 23939-24457 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"446","span":{"begin":178,"end":181},"obj":"Gene"},{"id":"447","span":{"begin":182,"end":185},"obj":"Gene"},{"id":"448","span":{"begin":90,"end":100},"obj":"Species"},{"id":"449","span":{"begin":337,"end":347},"obj":"Species"}],"attributes":[{"id":"A446","pred":"tao:has_database_id","subj":"446","obj":"Gene:3107"},{"id":"A447","pred":"tao:has_database_id","subj":"447","obj":"Gene:3123"},{"id":"A448","pred":"tao:has_database_id","subj":"448","obj":"Tax:2697049"},{"id":"A449","pred":"tao:has_database_id","subj":"449","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T220","span":{"begin":178,"end":181},"obj":"Body_part"},{"id":"T221","span":{"begin":182,"end":185},"obj":"Body_part"}],"attributes":[{"id":"A220","pred":"fma_id","subj":"T220","obj":"http://purl.org/sig/ont/fma/fma84079"},{"id":"A221","pred":"fma_id","subj":"T221","obj":"http://purl.org/sig/ont/fma/fma84795"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T41","span":{"begin":90,"end":94},"obj":"Disease"},{"id":"T42","span":{"begin":337,"end":341},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T184","span":{"begin":72,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T185","span":{"begin":126,"end":129},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T186","span":{"begin":158,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T187","span":{"begin":199,"end":202},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T188","span":{"begin":283,"end":290},"obj":"http://purl.obolibrary.org/obo/PR_000018263"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T187","span":{"begin":24,"end":31},"obj":"Chemical"},{"id":"T188","span":{"begin":118,"end":125},"obj":"Chemical"},{"id":"T189","span":{"begin":283,"end":290},"obj":"Chemical"}],"attributes":[{"id":"A187","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_53000"},{"id":"A188","pred":"chebi_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/CHEBI_53000"},{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}

{"project":"LitCovid-sentences","denotations":[{"id":"T200","span":{"begin":0,"end":13},"obj":"Sentence"},{"id":"T201","span":{"begin":14,"end":101},"obj":"Sentence"},{"id":"T202","span":{"begin":102,"end":266},"obj":"Sentence"},{"id":"T203","span":{"begin":267,"end":375},"obj":"Sentence"},{"id":"T204","span":{"begin":376,"end":518},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T459","span":{"begin":24,"end":31},"obj":"BV_9"},{"id":"T460","span":{"begin":90,"end":100},"obj":"SP_7"},{"id":"T461","span":{"begin":118,"end":125},"obj":"BV_9"},{"id":"T462","span":{"begin":178,"end":181},"obj":"GO:0042611"},{"id":"T463","span":{"begin":186,"end":193},"obj":"SO:0001023"},{"id":"T464","span":{"begin":314,"end":328},"obj":"BV_26"},{"id":"T465","span":{"begin":337,"end":347},"obj":"SP_7"},{"id":"T466","span":{"begin":412,"end":416},"obj":"UBERON:0000104"},{"id":"T16915","span":{"begin":337,"end":347},"obj":"SP_7"},{"id":"T18374","span":{"begin":24,"end":31},"obj":"BV_9"},{"id":"T95440","span":{"begin":90,"end":100},"obj":"SP_7"},{"id":"T19239","span":{"begin":118,"end":125},"obj":"BV_9"},{"id":"T52484","span":{"begin":178,"end":181},"obj":"GO:0042611"},{"id":"T40017","span":{"begin":186,"end":193},"obj":"SO:0001023"},{"id":"T51478","span":{"begin":314,"end":328},"obj":"BV_26"},{"id":"T11973","span":{"begin":337,"end":347},"obj":"SP_7"},{"id":"T50614","span":{"begin":412,"end":416},"obj":"UBERON:0000104"}],"text":"5 Conclusion\nITLCFTLKR epitope was selected for crafting and designing a vaccine against SARS-COV-2. This particular epitope has good antigenicity, exhibits active binding with MHC HLA-Alleles, and has maximum population coverage for different geographical regions. Therefore, this peptide can be further used in vaccine design against SARS-COV-2 after wet lab verification. This novel approach can also assist life science research groups to reduce time, monetary expenditures, as well as physical hit-trial efforts."}